Maryam Tehranipour | Pharmacology | Best Researcher Award

Published on by Health Scientists

Assoc. Prof. Dr. Maryam Tehranipour | Pharmacology | Best Researcher Award

Animal Physiology | Islamic Azad University | Iran

Dr. Maryam Tehranipour is an accomplished Associate Professor in the Department of Biology at the Islamic Azad University, Mashhad, Iran, recognized for her distinguished contributions to the fields of diabetes, metabolic disorders, neurobiology, oxidative stress, and cancer biology. Holding a Ph.D. in Animal Physiology, she has built a dynamic academic and research career integrating cellular physiology, pharmacology, and molecular mechanisms of disease. Her extensive publication record spans a broad spectrum of biomedical investigations, including neuroprotective strategies, natural product pharmacology, nanomedicine, and experimental models of diabetes and neurodegeneration. Dr. Tehranipour’s pioneering studies have elucidated the roles of oxidative damage, angiogenesis, and neuronal regeneration in disease progression and therapeutic recovery, particularly highlighting the potential of bioactive compounds and nanocarrier systems in drug design and targeted therapy. Her collaborative work has advanced understanding of diabetic complications, nerve injury repair, and cancer cell modulation through natural and synthetic agents. Beyond her prolific research output, she has played a significant role in mentoring undergraduate, graduate, and doctoral students, fostering scientific rigor and innovation in physiological research. Her scholarly influence is reflected through her indexed publications, contributions to interdisciplinary research networks, and global collaborations that link physiology, biochemistry, and nanotechnology for translational health impact. Dr. Tehranipour’s scientific endeavors emphasize the integration of experimental biology with clinical relevance, aiming to bridge laboratory discoveries with therapeutic applications. Through her ongoing research, she continues to contribute meaningfully to global biomedical science, particularly in developing sustainable and biologically safe therapeutic interventions addressing chronic and degenerative diseases that pose major public health challenges. She has 238 citations from 53 documents with an h-index of 9.

Profile: Scopus 

Featured Publications

1. The Umbelliprenin-CTAB cellulose nanocrystal delivery system prevents hyperglycemia in diabetic rats by activating the insulin receptor IR/PDK1 pathway. (2025). Scientific Reports. Open access.

2. The effects of N-butanol and ethyl acetate fractions of Ferula asafoetida hydroalcoholic extract on the expression of VEGF and FGF genes in the chorioallantoic membrane of chick embryos. (2025). Journal of Veterinary Research.Open access.

3. Bimetallic-based colorimetric aptasensor for the quantitative analysis of ampicillin using catalytic activity of ZrFe metal–organic framework and terminal deoxynucleotidyl transferase-assisted signal amplification. (2025). Bionanoscience. Open access.

4. The effect of Ziziphora clinopodioides hydroalcoholic extract on the neuronal density and histopathology of the hippocampal area CA2 in streptozotocin-induced Alzheimer’s model in male rats. (2025). Journal of Chemical Health Risks. Open access.

5. A novel alpha-terpineol-loaded niosome formulation coated with hyaluronic acid and evaluation of its anticancer properties in vitro. (2025). Journal of Molecular Liquids. Open access.

Reham Abdelkader | Pharmacology | Best Researcher Award

Published on by Health Scientists

Prof. Reham Abdelkader | Pharmacology | Best Researcher Award 

Head of department | German university in Cairo | Egypt

Dr. Reham Mahmoud Abdel-Kader, Professor of Pharmacology and Toxicology and Chair of the Department at the German University in Cairo, is a distinguished biomedical scientist whose research bridges molecular pharmacology, neurodegenerative diseases, and cancer biology with translational therapeutic innovation. Her scientific contributions focus on elucidating mitochondrial dysfunction, neuroinflammation, and cellular bioenergetics as critical mechanisms in Alzheimer’s disease and oncological disorders, advancing targeted treatment approaches through nanotechnology and pharmacogenomic insights. Dr. Abdel-Kader has established two active research groups investigating Alzheimer’s pathology and mitochondrial roles in breast cancer progression, fostering a strong translational link between bench discovery and therapeutic development. She has published widely in internationally recognized journals in pharmacology, neurobiology, and molecular medicine, and her work has received global recognition through prestigious conference presentations and features in leading scientific outlets. Her research has attracted significant international funding from agencies such as the Swiss National Science Foundation, DAAD-BMBF, and the Science and Technology Development Fund, reflecting the impact and sustainability of her scientific endeavors. A committed academic leader, she has played a vital role in curriculum development, accreditation processes, and capacity-building initiatives that enhance educational quality and research excellence within her institution. Dr. Abdel-Kader actively collaborates with leading scientists and institutions across Europe, including partnerships in Germany and Switzerland, fostering international scientific exchange and innovation. Her patent in nanocomposite synthesis further underscores her commitment to bridging pharmaceutical research and technology-based solutions. Through her scholarly rigor, mentorship, and collaborative leadership, Dr. Abdel-Kader continues to contribute significantly to global pharmacological sciences and to shaping the next generation of health researchers dedicated to advancing human health and societal well-being.

Profiles: Google Scholar | ORCID

Featured Publications

1. Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., & others. (2007). Mitochondrial dysfunction: The first domino in brain aging and Alzheimer’s disease? Antioxidants & Redox Signaling,

2. Abdel-Kader, R., Hauptmann, S., Keil, U., Scherping, I., Leuner, K., Eckert, A., & others. (2007). Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacological Research,

3. Eckert, G. P., Renner, K., Eckert, S. H., Eckmann, J., Hagl, S., Abdel-Kader, R. M., & others. (2012). Mitochondrial dysfunction—A pharmacological target in Alzheimer’s disease. Molecular Neurobiology,

4. Franke, C., Nöldner, M., Abdel-Kader, R., Johnson-Anuna, L. N., Wood, W. G., & others. (2007). Bcl-2 upregulation and neuroprotection in guinea pig brain following chronic simvastatin treatment. Neurobiology of Disease

5. Eckert, G. P., Schiborr, C., Hagl, S., Abdel-Kader, R., Müller, W. E., & Rimbach, G. (2013). Curcumin prevents mitochondrial dysfunction in the brain of the senescence-accelerated mouse-prone 8. Neurochemistry International.

Siyu Chen | Pharmacology | Best Researcher Award

Published on by Health Scientists

 Prof. Siyu Chen | Pharmacology | Best Researcher Award

Professor | China Pharmaceutical University | China

Dr. Chen Siyu currently serves as the Deputy Director of the Department of Biochemistry at the School of Life Sciences and Technology, China Pharmaceutical University, where he is also a Professor, Doctoral Supervisor, and Chief Young Scientist of the National Key Research and Development Program. He obtained his academic training in biochemistry and molecular biology, cultivating a strong foundation in metabolic and biochemical sciences. Dr. Chen’s research primarily focuses on Target Discovery and Intervention Strategies for Metabolic Diseases, aiming to elucidate molecular mechanisms and identify novel therapeutic targets for metabolic regulation. He has published extensively as first or corresponding author in leading international journals such as Advanced Science, Nature Communications, and Gut Microbes, with his work widely cited by peers. His innovative research has led to the granting of national patents and multiple ongoing patent applications. Dr. Chen has successfully led major research projects under national and provincial funding programs, including the National Key R&D Program for Young Scientists, the National Natural Science Foundation for Young Scientists, and the Jiangsu Province Excellent Youth Fund. Recognized for his scholarly excellence, he received the Outstanding Doctoral Dissertation Award of Jiangsu Province. In addition to his research, Dr. Chen contributes actively to the academic community as a Young Member of the Metabolism Committee of the Chinese Society of Biochemistry, Director of the Jiangsu Society of Developmental Biology, and Editorial Board Member of Journal of China Pharmaceutical University and Progress in Biochemistry and Biophysics. He also serves as a Guest Editor for Frontiers in Endocrinology and a regular reviewer for leading journals including Journal of Hepatology and ACS Nano. He has 1616 citations from 60 documents with an h-index of 24.

Profiles: Scopus | ORCID

Featured Publications

1. Photosensitive biomimetic nanomedicine-mediated recombination of adipose microenvironments for antiobesity therapy. (2025). Advanced Materials.

2. Wearable photobiomodulation halts thyroid cancer growth by leveraging thyroid photosensitivity. (2025). Bioengineering and Translational Medicine.

3. Blue light-driven cell cycle arrest in thyroid cancer via Retinal-OPN3 complex. (2024). Cell Communication and Signaling.

4. Luteolin detoxifies DEHP and prevents liver injury by degrading Uroc1 protein in mice. (2024). EMBO Molecular Medicine.

5. Rhodiolin inhibits the PI3K/AKT/mTOR signaling pathway via the glycolytic enzyme GPI in human papillary thyroid cancer. (2024). Phytomedicine.

Milad Rahimzadegan | Pharmacology | Best Academic Researcher Award

Published on by Health Scientists

Assist. Prof. Dr. Milad Rahimzadegan | Pharmacology | Best Academic Researcher Award

Assistant Professor | Shahid Beheshti University of Medical Sciences | Iran

Dr. Milad Rahimzadegan is an Assistant Professor at the Functional Neurosurgery Research Center, Shahid Beheshti University of Medical Sciences, and serves as R&D Manager in multiple pharmaceutical companies. He earned his PhD in Pharmacy-Toxicology and Pharmacology from Tehran University of Medical Sciences, followed by an M.Sc. in Medical Toxicology from Tarbiat Modares University, and a B.A. in Plant Medicine from the University of Tehran. Recently, he completed a post-doctoral fellowship focused on Artificial Intelligence in Neuroscience at the Functional Neurosurgery Research Center. Dr. Rahimzadegan’s research spans neuropharmacology, neurotoxicology, regenerative medicine, and advanced drug delivery systems, with particular emphasis on stem cell differentiation, conductive scaffolds for spinal cord injury, and nano-biosensing for cardiovascular and neurodegenerative diseases. He has authored numerous high-impact publications in journals including Stem Cell Reviews and Reports, International Journal of Biological Macromolecules, Materials Science & Engineering C, and Carbohydrate Polymers, and has contributed to multiple books on pharmacology, regenerative medicine, and neurosurgery. His work has been recognized with awards such as the Top Academic Secretary of USERN Iran, Young Scientific Award at Shahid Beheshti University, and membership in Iran’s National Elites Foundation. In addition to his research contributions, he serves as a reviewer and editorial board member for journals including Interventional Pain Medicine and Neuromodulation and International Clinical Neuroscience Journal, reflecting his commitment to advancing scientific knowledge and fostering innovation in neuroscience, pharmacology, and translational medicine. He has 326 citations from 26 documents with an h-index of 11.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Rahimzadegan, M., & Soodi, M. (2018). Comparison of memory impairment and oxidative stress following single or repeated doses administration of scopolamine in rat hippocampus.

2. Asl, S. K., & Rahimzadegan, M. (2022). The recent progress in the early diagnosis of acute myocardial infarction based on myoglobin biomarker: Nano-aptasensors approaches.

3. Malek-Khatabi, A., Razavi, M. S., Abdollahi, A., & Rahimzadeghan, M., et al. (2023). Recent progress in PLGA-based microneedle-mediated transdermal drug and vaccine delivery.

4. Asl, S. K., Rahimzadegan, M., & Asl, A. K. (2024). Progress in cardiac tissue engineering and regeneration: Implications of gelatin-based hybrid scaffolds.

5. Asl, S. K., Rahimzadegan, M., & Ostadrahimi, R. (2024). The recent advancement in the chitosan hybrid-based scaffolds for cardiac regeneration after myocardial infarction.